PET/CT to Identify "Vulnerable" Arterial Plaque

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2006 by Rambam Health Care Campus.
Recruitment status was  Recruiting
Information provided by:
Rambam Health Care Campus Identifier:
First received: December 26, 2006
Last updated: NA
Last verified: November 2006
History: No changes posted

The purpose of this research is to evaluate the presence, location and intensity of FDG uptake in the large arteries using the new technology of fused PET/CT imaging and to compare FDG uptake with the presence of arterial calcifications as seen on the simultaneously acquired CT, in order to determine if FDG was increases incalcified plaque or in a different location in the arterial wall. we will also evaluate the relationship between FDG localization and future cardiovascular events in out patient population

Condition Intervention
Device: PET/CT imaging

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: PET/CT to Identify "Vulnerable" Arterial Plaque

Resource links provided by NLM:

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • the impact of the imaging modality on patient management

Secondary Outcome Measures:
  • the impact of the imaging modality on patient management

Estimated Enrollment: 800
Study Start Date: April 2004

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients referred for clinical FDG-PET/CT studies
  • Patients 50 yr or older
  • Patients signed informed consent

Exclusion Criteria:

  • Patients unable or unwilling to tolerate the scan until its completion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00416065

Contact: Ora Israel, MD 972-4-8543009

Rambam Medical Center Recruiting
Haifa, Israel
Contact: Ora Israel, MD    972-4-8543009   
Sponsors and Collaborators
Rambam Health Care Campus
Principal Investigator: Ora Israel, MD Rambam Health Care Campus
  More Information

No publications provided Identifier: NCT00416065     History of Changes
Other Study ID Numbers: plaqueCTIL
Study First Received: December 26, 2006
Last Updated: December 26, 2006
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration processed this record on October 13, 2015